Introduction. The angiotensin-converting enzyme (ACE) intron 16 insertion/deletion (I/D) polymorphism is associated with ACE activity and has been discussed as a risk factor for pre-eclampsia. Disturbances of uteroplacental circulation are involved in the pathogenesis of pre-eclampsia. In this study, we tested whether the ACE I/D genotype is associated with history of foetal loss (FL) or uteroplacental dysfunction (UPD). Patients and methods. ACE I/D genotype was determined in 312 women presenting with a history of FL and 112 women admitted because of UPD. The association of the ACE I/D genotype with FL or UPD was assessed in a case-control study using 527 patients with diagnoses other than FL or UPD. To exclude potential biases due to associations of this genotype with other diagnoses, we additionally performed a casecontrol study using 553 healthy controls. Results. ACE I/D genotype was significantly associated with history of FL in both case-control studies (patient controls: odds ratio 1.52, p<0.02; healthy controls: odds ratio 1.48, p=0.02). There was no evidence for allele-dose dependency. No association of the ACE I/D genotype with UPD could be detected. Conclusions. The ACE I/D genotype exhibits a statistically significant association with a history of FL. These results corroborate an involvement of the renin-angiotensin system in pregnancy complications.
Introduction
Vascular endothelial dysfunction plays an important role in the pathogenesis of pregnancy complications, 1 and impaired uteroplacental circulation indicated by increased impedance to flow, notching, or foetal growth restriction is a putative precursor to pre-eclampsia and foetal loss. 2 Different studies have indicated an involvement of insulin resistance, dyslipidaemia, and inflammation in the pathogenesis of pre-eclampsia. 3 Furthermore, it is assumed that the reninangiotensin-aldosterone system is part of a pathway implicated in the pathogenesis of different pregnancy complications. 4 In particular, the intron 16 insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE), which critically influences plasma ACE activity 5, 6 and angiotensin peptide levels, 7 and which is implicated in the pathogenesis of different diseases, 8,9 is discussed as a possible genetic risk factor for pre-eclampsia. 10, 11 Moreover, there are a few studies indicating a possible influence of the ACE I/D genotype on risk of foetal loss (FL) under certain circumstances. 12, 13 In the present study, we tested the hypothesis that the ACE I/D genotype is associated with FL and/or uteroplacental insufficiency.
Materials and methods

Study population
We studied the association of the ACE intron 16 I/D polymorphism with history of FL (n=312) in patients presenting during January 3 rd 2005 to July 3 rd 2006 in our haemostaseologic outpatient unit for medical attendance. One hundred and seventy-seven of these women presented with a history of recurring FL (≥ 2 first-trimester FL). During the observation period, 527 patients, which were included in a patient control group, presented with diagnoses other than FL. Main diagnoses were history of venous thromboembolism (VTE) (n=392), uteroplacental insufficiency (foetal growth restriction, high impedance to flow, notching) (n=112), and history of atherothrombotic disease (n=52). Additionally, a healthy control group was made up of 553 healthy women presenting in our institution without history of FL, VTE, uteroplacental dysfunction (UPD), and atherothrombotic disease. 14 The study was approved by the local ethics committee, and the patients were enrolled after giving informed consent.
ACE intron 16 I/D genotyping
The ACE intron 16 I/D genotypes were characterised by amplification fragment length polymorphisms, as described previously. 15 Briefly, after extraction of genomic DNA from whole blood using GenoPrep TM Cartridges B and the GenoM TM -6 system (GenoVision, Vienna, Austria), a primer pair consisting of 5' GAC CTG CTG CCT ATA CAG T 3' and 5' GGG TAA AAC TGG AGG ATG GCT C 3' was used for amplification, generating a 234-bp product for the ACE intron 16 D allele, and a 521-bp amplification product for the ACE intron 16 I allele. Additionally, the primer pair 5' GAT TAC AGG CGT GAT ACA GT 3' and 5' GGG TAA AAC TGG AGG ATG GCT C 3', which is specific for the ACE intron 16 I allele, was used. All primers were synthesised by TIB Molbiol (Berlin, Germany).
Statistical analyses
The ACE intron 16 I/D polymorphism was assessed by Pearson c 2 tests to determine if the observed genotype distribution was in accordance with expected Hardy-Weinberg proportions. Association of the ACE intron 16 I/D genotype with FL or UPD was assessed by c 2 -testing. For calculations on the allele-dose dependency of this association, the ACE intron 16 II genotype was used as the reference group, and a test for linear trend of the log odds (trend test) was performed. Odds ratios (OR) and the 95% confidence intervals (95% CI) are presented. All statistical analyses were performed using Stata Statistical Software for Macintosh, release 10.0 (StataCorp, USA).
Results
The frequencies of the ACE intron 16 I/D genotypes as well as the clinical characteristics of the different study populations are given in table 1. There was no evidence for deviation from Hardy-Weinberg equilibrium. While in women with a history of FL carriage of the ACE D allele was considerably more frequent (81.5%) in comparison to both control groups (patient controls: 73.5%; healthy controls: 74.7%) and the group of patients presenting with UPD (72.3%), the carriage rates between the control groups were nearly exactly the same.
Carriage of the ACE intron 16 D allele was significantly associated with history of FL (table 2) . There was no difference between analyses performed using either the patient control group (table 2, case-control 1) or the control group consisting of healthy individuals ( Finally, we tested the association of the ACE I/D genotype with UPD (table 3) . In these analyses, no significant association between ACE I/D and UPD could be detected. However, the statistical power for these analyses was low (power=0.44). 
Discussion
Disturbations in the renin-angiotensin-aldosterone system and the uteroplacental function are implicated in the pathogenesis of different pregnancy complications like pre-eclampsia and FL. 2, 4 As the contribution of the ACE intron 16 I/D polymorphism to the inter-individual variation of ACE levels is well documented, 5,6 studies elucidating its role in the evolvement of FL or UPD are obviously indicated. Apart from studies which implicate the ACE I/D genotype with susceptibility to pre-eclampsia or preterm delivery, 10, 11, 16 there are only two small studies which indicate a possible influence of this genetic variant on the risk for FL. 12, 13 The first study investigated the association of different hereditary thrombophilic risk factors (prothrombin 20210G→A, factor V Leiden, angiotensin type 1 receptor 1166A→C, and ACE intron 16 I/D) with risk of FL in a small case-control study (n=55+70). 13 Although in this study there was no statistically significant association between ACE D allele carrier status or D allele number with FL, the relation of FL and carriage of two ACE D alleles reached a sufficient level of statistical significance (OR 2.3, p<0.03). 13 However, in these analyses no correction for multiple testing was performed. The second report on this topic performed analyses on the influence of prothrombin 20210G→A, factor V Leiden, methylenetetrahydrofolate reductase 677C→T, plasminogen activator inhibitor-1 -675 4G/5G, and ACE intron 16 I/D on risk of FL. 12 In this study, risk of FL was significantly dependent on ACE I/D genotype in individuals with the plasminogen activator inhibitor-1 -675 4G/4G genotype. 12 However, as in the first study, no correction for multiple testing was done. Table 3 Association of the angiotensin-converting enzyme intron 16 insertion/deletion polymorphism with uteroplacental dysfunction In the present study, we primarily tested the hypothesis that the ACE intron 16 I/D polymorphism is associated with risk of FL. As presented in table 2, in our study population there was a significant association of this genetic variant with risk of FL. As there is a continuing discussion about potential biases in the selection of control groups 17 -on the one hand, a cohort of healthy blood donors is assumed to be somewhat artificial, on the other, patient control groups are potentially biased by other associations between the genetic trait of interest and other diagnoses -we decided to perform analyses on two different control groups. First, we used a patient control group consisting of individuals admitted to our institution with diagnoses other than FL. As a main diagnosis of our patient control group was VTE, and there is discussion about a possible weak association of this disease with the ACE I/D genotype, 18, 19 the association, which we identified between this genotype and FL (OR 1.52, 95% CI 1.07-2.19), will rather underestimate this relation. In a second analysis using healthy individuals as a control group, the strength of association between the ACE I/D genotype and FL was almost exactly the same (OR 1.48, 95% CI 1.04-2.13). Thus, a potential bias due to the selection of the control group seems to be unlikely. The question, whether the association between the ACE intron 16 I/D polymorphism and FL is mediated by its influence on other pregnancy complications like UPD or preeclampsia 10, 11, 16 cannot be answered based on our data. Although in our study population no association of the ACE I/D genotype with UPD could be identified, the statistical power of this analysis was too low to exclude this possibility explicitly. Moreover, in our study only three women presenting with a documented history of pre-eclampsia have been included. This number makes a statistical assessment in respect of this disease impossible. Further studies are needed to address the questions, how the association between the ACE intron 16 I/D polymorphism and FL is mediated, and whether this relation could give an opportunity for therapeutic intervention.
